Oxis Intl Inc (OXIS) 0.2000 $OXIS
Oxis Biotech Signs Exclusive License Agreement With University Of Minnesota For Novel NK Cell TriKE Targeted Immunotherapy Platform Technology
ACCESSWIRE - Mon Jul 25, 6:30AM CDT
LOS ANGELES, CA / ACCESSWIRE / July 25, 2016 / Oxis International Inc. (OTCQB: OXIS and Euronext Paris OXI.PA) announced today that its wholly owned subsidiary, Oxis Biotech Inc., has entered into an agreement with the University of Minnesota to develop and commercialize cancer therapies using Trispecific Killer Engager (TriKE) technology developed by researchers at the university to target NK cells to cancer.
KITE: 54.22 (-0.01), JUNO: 29.76 (-0.61)
Oxis International's Innovative Cancer Therapies Will Be Profiled on Fox Business Network
ACCESSWIRE - Tue Jul 19, 6:30AM CDT
LOS ANGELES, CA / ACCESSWIRE / July 19, 2016 / Oxis International Inc. (OTCQB: OXIS and Euronext Paris OXI.PA) announced today that the company's innovative cancer therapies will be profiled on Fox Business Network on Sunday, July 24, at 12:30 p.m. Eastern time.
Oxis International Issues Letter to Shareholders
ACCESSWIRE - Wed Jul 13, 6:30AM CDT
LOS ANGELES, CA / ACCESSWIRE / July 13, 2016 / Oxis International Inc. (OTC: OXIS and OXI.PA), a biotechnology company focused on immunotherapies for the treatment of cancer, announced today that Chairman and CEO Anthony Cataldo has issued the following letter to stockholders.
Oxis Adds New Patients in Phase 1/Phase 2 Clinical Trial of Key Cancer Drug OXS-1550
ACCESSWIRE - Mon Jul 11, 6:30AM CDT
LOS ANGELES, CA / ACCESSWIRE / July 11, 2016 / Oxis International Inc. (OTC: OXIS and OXI.PA), a biotechnology company focused on immunotherapies for the treatment of cancer, announced today that it has enrolled six new patients in a Phase 1/Phase 2 trial of its most promising cancer drug, OXS-1550.
Oxis Begins Enrolling and Treating Patients in FDA Phase 1/Phase 2 Clinical Trial of Key Cancer Drug OXS-1550
ACCESSWIRE - Thu Jun 23, 6:31AM CDT
LOS ANGELES, CA / ACCESSWIRE / June 23, 2016 / Oxis International, Inc. (OTCQB: OXIS and Euronext Paris: OXI.PA), a biotechnology company focused on immunotherapies for the treatment of cancer, announced today that it has begun enrolling patients in a Phase 1/Phase 2 trial of its most promising cancer drug, OXS-1550.
Four Stocks Hitting New Highs On Tuesday
ACCESSWIRE - Tue Jun 21, 1:23PM CDT
CORAL GABLES, FL / ACCESSWIRE / June 21, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. LifeClips Inc. (OTCQB: LCLP), PhotoMedex, Inc. (NASDAQ: PHMD), Oxis International, Inc. (OTCQB: OXIS), and Delta Technology Holdings Limited (NASDAQ: DELT) have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the OTC, Nasdaq and NYSE subscribe to our newsletter at DailyStockReporter.com.
PHMD: 0.23 (-0.02), DELT: 2.90 (+1.84)
Four Emerging Companies That Are On Everyone's Radar, Today June 16
PR Newswire - Thu Jun 16, 11:00AM CDT
DailyStockReporter.com Briefing: The overall markets traded lower Thursday morning as oil slid in price. Energy traded more than 1.5% lower as the biggest loser in the S&P 500, followed by financials. U.S. crude oil futures traded more than 2.5% lower to under $47 a barrel. But in light of this, other stocks have traded higher during Thursday's morning session on momentum and above average volume. Four stocks that are being traded heavily before 11AM EST have been given a full breakdown below:
MDVX: 1.38 (-0.05), GEVO: 0.53 (-0.01)
CEO Tony Cataldo to Present at the LD Micro Invitational Conference
ACCESSWIRE - Fri Jun 03, 8:00AM CDT
LOS ANGELES, CA / ACCESSWIRE / June 3, 2016 / Oxis Biotech Inc., a wholly owned subsidiary of Oxis International Inc. (OTCQB: OXIS and Euronext Paris: OXI.PA), announced that CEO Tony Cataldo will be presenting at the LD Micro Invitational Conference on June 7, 2016, at 3:00pm PST. The conference will be held on June 7-9 at the Luxe Hotel on Sunset Boulevard in Los Angeles, California.
Oxis International Completes Bridge Financing
ACCESSWIRE - Wed May 18, 8:00AM CDT
LOS ANGELES, CA / ACCESSWIRE / May 18, 2016 / Oxis International, Inc. (OTCQB: OXIS) and (Euronext Paris: OXI.PA) announced today that it has closed on a bridge financing of $1,223,138.00.
Oxis Praises Biden's 'Cancer Moonshot,' Says its Portfolio of Targeted Immunotherapies Provides Next-Generation Cancer Treatments
PR Newswire - Thu Mar 31, 7:00AM CDT
Oxis Biotech Inc., a wholly owned subsidiary of Oxis International Inc. [OTC: OXIS and Euronext Paris: OXI.PA], expressed its support of the "cancer moonshot," which seeks to incentivize cooperation between the government and the private sector in the development of new treatments for cancer.
Bispecific Immunotherapy, The Basis For Oxis' Cancer Drug, Lauded As Promising Alternative To CAR-T Therapy
PR Newswire - Tue Mar 22, 7:00AM CDT
Oxis Biotech Inc., a wholly owned subsidiary of Oxis International Inc. [OTC: OXIS and Euronext Paris: OXI.PA], announced today that the bispecific cancer immunotherapy approach on which its leading drug is based was lauded as a promising alternative to expensive CAR-T therapy.
JUNO: 29.76 (-0.61)
Oxis Celebrates 'Clinical Trial Triumph' As Patient Passes 18 Months In Complete Cancer Remission
PR Newswire - Wed Feb 10, 8:48AM CST
Oxis International Inc. (OTC/QB: OXIS) announced today that the company's blood cancer drug, OXS-1550, was described as a "clinical trial triumph" after one of the first patients treated with the drug went into complete cancer remission.
Oxis Chairman And CEO Tells Shareholders Biotech Company Making 'Substantial Progress' With Lead Cancer Drug, Drawing Closer To NASDAQ Listing
PR Newswire - Tue Feb 02, 7:00AM CST
Oxis International Inc. (OTC-QB: OXIS) and its subsidiary, Oxis Biotech Inc., a company developing a novel prodrug therapeutic for the treatment of cancer, announced today that Chairman and CEO Anthony Cataldo has issued the following letter to stockholders.
Oxis Biotech - University of Minnesota Masonic Cancer Center Receive FDA Allowance To Proceed With OXS-1550 (DT2219ARL) Phase 1 / Phase 2 Clinical Trial
PR Newswire - Mon Nov 23, 7:00AM CST
Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc. [OTC: OXIS] and [Euronext Paris: OXI.PA] announced today its collaborators at the University of Minnesota Masonic Cancer Center received notification from the U.S. Food and Drug Administration (FDA) that they can proceed with their planned combination Phase 1/Phase 2 clinical trial for OXS-1550. Oxis holds worldwide exclusive rights to develop and commercialize OXS-1550, a novel therapy for the treatment of leukemia and lymphoma.
Oxis International, Inc. Announces Appointment of Michael S. Sitrick to Business Advisory Board
PR Newswire - Mon Oct 05, 7:00AM CDT
Oxis International, Inc. [OTC: OXIS] [Euronext Paris: OXI.PA] announced today that Michael S. Sitrick has joined its Business Advisory Board. Oxis is in the process of building a world class Business Advisory Board to assist management in strategy, development and execution. The Business Advisory Board members will become members of the Oxis Board of Directors upon a successful up-listing to the NASDAQ exchange.
Oxis Biotech Inc. Announces Appointment of Randolph C Read to Business Advisory Board
PR Newswire - Thu Sep 24, 6:30AM CDT
Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc. [OTC: OXIS] and [Euronext Paris: OXI.PA] announced today, Randolph C Read has joined its Business Advisory Board. Oxis is in the process of building a world class Advisory Board to assist management in strategy, development and execution. The Business Advisory Board members will become members of the Oxis Board of Directors upon a successful up-listing to the NASDAQ exchange.
Oxis Biotech, Inc. Announces Appointment of James L. Nelson to Board
PR Newswire - Tue Sep 15, 7:01AM CDT
Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc. [OTC: OXIS] and [Euronext Paris: OXI.PA], announced today that James L. Nelson has joined its Business Advisory Board. Oxis is in the process of building a world class Advisory Board to assist management in strategy, development and execution. The Business Advisory Board members will become members of the Oxis Board of Directors upon a successful up-listing to the NASDAQ exchange.
HLF: 66.88 (-0.21), VLTC: 3.29 (-0.01)
DUE DILIGENCE REPORT: Four Players are Examined in a Large and Rapidly Growing Market
ACCESSWIRE - Mon Sep 14, 7:35AM CDT
NEW YORK, NY / ACCESSWIRE / September 14, 2015 / According to Arc View Market Research, the market for legal marijuana reached $2.7 billion in sales for 2014, growing from $1.53 billion in 2013. This growth is expected to continue, with the market increasing by 32% in 2015, and reaching $10.2 billion by 2018. Between 2009 and 2014, the cannabis industry grew 16.2% annually, and growth is expected to increase to 23.3% annually between 2014 and 2019. Cannabis is currently the fastest growing industry in the United States. If marijuana is legalized at the federal level, revenues for the legal cannabis industry could reach $35 billion by 2020 according to Greenwave Advisors. Currently, 23 states have legalized medical marijuana, and two states, Washington and Colorado, have legalized marijuana for recreational use.
Oxis Biotech to present at the Rodman Renshaw Global Investment Conference
PR Newswire - Wed Sep 09, 6:56AM CDT
Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc. [OTC: OXIS] and [Euronext Paris: OXI.PA] announced today the company will be presenting at the 2015 Rodman & Renshaw Global Investment Conference in New York City.
Analyst Coverage Initiated on Oxis International, Inc. (OXIS) with Speculative Buy Rating Following Recent Corporate Announcements
ACCESSWIRE - Wed Aug 12, 9:48AM CDT
MIAMI, FL / ACCESSWIRE / August 12, 2015 / The immunotherapy market, the market of treatments that use your body's own immune system to help fight cancer, is positioned for exponential growth in the next 5-10 years. It stood at $1.1 billion in 2012 and is expected to grow to at least $9 billion by 2022. That yields a 15.08% expected CAGR for the immunotherapy market, giving one of the highest expected growth rates of any market over the next 5-10 years.
Oxis Biotech Signs Exclusive License Agreement With University Of Minnesota For Novel NK Cell TriKE Targeted Immunotherapy Platform Technology
ACCESSWIRE - Mon Jul 25, 6:30AM CDT
LOS ANGELES, CA / ACCESSWIRE / July 25, 2016 / Oxis International Inc. (OTCQB: OXIS and Euronext Paris OXI.PA) announced today that its wholly owned subsidiary, Oxis Biotech Inc., has entered into an agreement with the University of Minnesota to develop and commercialize cancer therapies using Trispecific Killer Engager (TriKE) technology developed by researchers at the university to target NK cells to cancer.
KITE: 54.22 (-0.01), JUNO: 29.76 (-0.61)
Oxis International's Innovative Cancer Therapies Will Be Profiled on Fox Business Network
ACCESSWIRE - Tue Jul 19, 6:30AM CDT
LOS ANGELES, CA / ACCESSWIRE / July 19, 2016 / Oxis International Inc. (OTCQB: OXIS and Euronext Paris OXI.PA) announced today that the company's innovative cancer therapies will be profiled on Fox Business Network on Sunday, July 24, at 12:30 p.m. Eastern time.
Oxis International Issues Letter to Shareholders
ACCESSWIRE - Wed Jul 13, 6:30AM CDT
LOS ANGELES, CA / ACCESSWIRE / July 13, 2016 / Oxis International Inc. (OTC: OXIS and OXI.PA), a biotechnology company focused on immunotherapies for the treatment of cancer, announced today that Chairman and CEO Anthony Cataldo has issued the following letter to stockholders.
Oxis Adds New Patients in Phase 1/Phase 2 Clinical Trial of Key Cancer Drug OXS-1550
ACCESSWIRE - Mon Jul 11, 6:30AM CDT
LOS ANGELES, CA / ACCESSWIRE / July 11, 2016 / Oxis International Inc. (OTC: OXIS and OXI.PA), a biotechnology company focused on immunotherapies for the treatment of cancer, announced today that it has enrolled six new patients in a Phase 1/Phase 2 trial of its most promising cancer drug, OXS-1550.
Oxis Begins Enrolling and Treating Patients in FDA Phase 1/Phase 2 Clinical Trial of Key Cancer Drug OXS-1550
ACCESSWIRE - Thu Jun 23, 6:31AM CDT
LOS ANGELES, CA / ACCESSWIRE / June 23, 2016 / Oxis International, Inc. (OTCQB: OXIS and Euronext Paris: OXI.PA), a biotechnology company focused on immunotherapies for the treatment of cancer, announced today that it has begun enrolling patients in a Phase 1/Phase 2 trial of its most promising cancer drug, OXS-1550.
Four Stocks Hitting New Highs On Tuesday
ACCESSWIRE - Tue Jun 21, 1:23PM CDT
CORAL GABLES, FL / ACCESSWIRE / June 21, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. LifeClips Inc. (OTCQB: LCLP), PhotoMedex, Inc. (NASDAQ: PHMD), Oxis International, Inc. (OTCQB: OXIS), and Delta Technology Holdings Limited (NASDAQ: DELT) have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the OTC, Nasdaq and NYSE subscribe to our newsletter at DailyStockReporter.com.
PHMD: 0.23 (-0.02), DELT: 2.90 (+1.84)
Four Emerging Companies That Are On Everyone's Radar, Today June 16
PR Newswire - Thu Jun 16, 11:00AM CDT
DailyStockReporter.com Briefing: The overall markets traded lower Thursday morning as oil slid in price. Energy traded more than 1.5% lower as the biggest loser in the S&P 500, followed by financials. U.S. crude oil futures traded more than 2.5% lower to under $47 a barrel. But in light of this, other stocks have traded higher during Thursday's morning session on momentum and above average volume. Four stocks that are being traded heavily before 11AM EST have been given a full breakdown below:
MDVX: 1.38 (-0.05), GEVO: 0.53 (-0.01)
CEO Tony Cataldo to Present at the LD Micro Invitational Conference
ACCESSWIRE - Fri Jun 03, 8:00AM CDT
LOS ANGELES, CA / ACCESSWIRE / June 3, 2016 / Oxis Biotech Inc., a wholly owned subsidiary of Oxis International Inc. (OTCQB: OXIS and Euronext Paris: OXI.PA), announced that CEO Tony Cataldo will be presenting at the LD Micro Invitational Conference on June 7, 2016, at 3:00pm PST. The conference will be held on June 7-9 at the Luxe Hotel on Sunset Boulevard in Los Angeles, California.
Oxis International Completes Bridge Financing
ACCESSWIRE - Wed May 18, 8:00AM CDT
LOS ANGELES, CA / ACCESSWIRE / May 18, 2016 / Oxis International, Inc. (OTCQB: OXIS) and (Euronext Paris: OXI.PA) announced today that it has closed on a bridge financing of $1,223,138.00.
Oxis Praises Biden's 'Cancer Moonshot,' Says its Portfolio of Targeted Immunotherapies Provides Next-Generation Cancer Treatments
PR Newswire - Thu Mar 31, 7:00AM CDT
Oxis Biotech Inc., a wholly owned subsidiary of Oxis International Inc. [OTC: OXIS and Euronext Paris: OXI.PA], expressed its support of the "cancer moonshot," which seeks to incentivize cooperation between the government and the private sector in the development of new treatments for cancer.
Bispecific Immunotherapy, The Basis For Oxis' Cancer Drug, Lauded As Promising Alternative To CAR-T Therapy
PR Newswire - Tue Mar 22, 7:00AM CDT
Oxis Biotech Inc., a wholly owned subsidiary of Oxis International Inc. [OTC: OXIS and Euronext Paris: OXI.PA], announced today that the bispecific cancer immunotherapy approach on which its leading drug is based was lauded as a promising alternative to expensive CAR-T therapy.
JUNO: 29.76 (-0.61)
Oxis Celebrates 'Clinical Trial Triumph' As Patient Passes 18 Months In Complete Cancer Remission
PR Newswire - Wed Feb 10, 8:48AM CST
Oxis International Inc. (OTC/QB: OXIS) announced today that the company's blood cancer drug, OXS-1550, was described as a "clinical trial triumph" after one of the first patients treated with the drug went into complete cancer remission.
Oxis Chairman And CEO Tells Shareholders Biotech Company Making 'Substantial Progress' With Lead Cancer Drug, Drawing Closer To NASDAQ Listing
PR Newswire - Tue Feb 02, 7:00AM CST
Oxis International Inc. (OTC-QB: OXIS) and its subsidiary, Oxis Biotech Inc., a company developing a novel prodrug therapeutic for the treatment of cancer, announced today that Chairman and CEO Anthony Cataldo has issued the following letter to stockholders.
Oxis Biotech - University of Minnesota Masonic Cancer Center Receive FDA Allowance To Proceed With OXS-1550 (DT2219ARL) Phase 1 / Phase 2 Clinical Trial
PR Newswire - Mon Nov 23, 7:00AM CST
Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc. [OTC: OXIS] and [Euronext Paris: OXI.PA] announced today its collaborators at the University of Minnesota Masonic Cancer Center received notification from the U.S. Food and Drug Administration (FDA) that they can proceed with their planned combination Phase 1/Phase 2 clinical trial for OXS-1550. Oxis holds worldwide exclusive rights to develop and commercialize OXS-1550, a novel therapy for the treatment of leukemia and lymphoma.
Oxis International, Inc. Announces Appointment of Michael S. Sitrick to Business Advisory Board
PR Newswire - Mon Oct 05, 7:00AM CDT
Oxis International, Inc. [OTC: OXIS] [Euronext Paris: OXI.PA] announced today that Michael S. Sitrick has joined its Business Advisory Board. Oxis is in the process of building a world class Business Advisory Board to assist management in strategy, development and execution. The Business Advisory Board members will become members of the Oxis Board of Directors upon a successful up-listing to the NASDAQ exchange.
Oxis Biotech Inc. Announces Appointment of Randolph C Read to Business Advisory Board
PR Newswire - Thu Sep 24, 6:30AM CDT
Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc. [OTC: OXIS] and [Euronext Paris: OXI.PA] announced today, Randolph C Read has joined its Business Advisory Board. Oxis is in the process of building a world class Advisory Board to assist management in strategy, development and execution. The Business Advisory Board members will become members of the Oxis Board of Directors upon a successful up-listing to the NASDAQ exchange.
Oxis Biotech, Inc. Announces Appointment of James L. Nelson to Board
PR Newswire - Tue Sep 15, 7:01AM CDT
Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc. [OTC: OXIS] and [Euronext Paris: OXI.PA], announced today that James L. Nelson has joined its Business Advisory Board. Oxis is in the process of building a world class Advisory Board to assist management in strategy, development and execution. The Business Advisory Board members will become members of the Oxis Board of Directors upon a successful up-listing to the NASDAQ exchange.
HLF: 66.88 (-0.21), VLTC: 3.29 (-0.01)
DUE DILIGENCE REPORT: Four Players are Examined in a Large and Rapidly Growing Market
ACCESSWIRE - Mon Sep 14, 7:35AM CDT
NEW YORK, NY / ACCESSWIRE / September 14, 2015 / According to Arc View Market Research, the market for legal marijuana reached $2.7 billion in sales for 2014, growing from $1.53 billion in 2013. This growth is expected to continue, with the market increasing by 32% in 2015, and reaching $10.2 billion by 2018. Between 2009 and 2014, the cannabis industry grew 16.2% annually, and growth is expected to increase to 23.3% annually between 2014 and 2019. Cannabis is currently the fastest growing industry in the United States. If marijuana is legalized at the federal level, revenues for the legal cannabis industry could reach $35 billion by 2020 according to Greenwave Advisors. Currently, 23 states have legalized medical marijuana, and two states, Washington and Colorado, have legalized marijuana for recreational use.
Oxis Biotech to present at the Rodman Renshaw Global Investment Conference
PR Newswire - Wed Sep 09, 6:56AM CDT
Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc. [OTC: OXIS] and [Euronext Paris: OXI.PA] announced today the company will be presenting at the 2015 Rodman & Renshaw Global Investment Conference in New York City.
Analyst Coverage Initiated on Oxis International, Inc. (OXIS) with Speculative Buy Rating Following Recent Corporate Announcements
ACCESSWIRE - Wed Aug 12, 9:48AM CDT
MIAMI, FL / ACCESSWIRE / August 12, 2015 / The immunotherapy market, the market of treatments that use your body's own immune system to help fight cancer, is positioned for exponential growth in the next 5-10 years. It stood at $1.1 billion in 2012 and is expected to grow to at least $9 billion by 2022. That yields a 15.08% expected CAGR for the immunotherapy market, giving one of the highest expected growth rates of any market over the next 5-10 years.
